GlaxoSmithKline (GSK) has decided to transfer its manufacturing operation in Costa Rica after reviewing its global manufacturing network and identifying production capacity available in other sites in its network in Latin America. The transfer of the product lines manufactured in Cost Rica will be done gradually over a period of three years that will end in 2019, the company said in a press release.

GSK is planning to transfer the production and packaging of soluble effervescent sachet products, Eno & Andrews, to a GSK manufacturing site in Buenos Aires, Argentina and the production and packaging of Panadol (paracetamol) liquid products to a GSK manufacturing site in Xochimilco, Mexico, a GSK spokesperson said.

The company’s Pharmaceutical and Consumer Healthcare division and its Business Services Center will remain in Cost Rica. To date, 500 people are employed within GSK’s business units in Costa Rica.

This process will not impact the supply of products in Costa Rica and consumers will continue to have access to GSK products. GSK said this decision is not reflective of the performance of its employees or Costa Rica’s competitiveness.

Source: GlaxoSmithKline